Comparative Lessons

OGB’s Shortcut to Niche Banking: $250 million SPAC merger with DAAQ
Author Image

Judy Lin

Feb 14, 2026

Old Glory Bank is wagering its century-old charter on crypto, pursuing a $250 million SPAC merger to fuse FDIC-insured banking with stablecoins, instant on-off ramps, and youth-driven digital demand—while balancing strict regulation against its promise of financial autonomy.

Taiwanese SL Bio Merges With Horizon Space Acquisition
Author Image

Lilit Voskoff

Feb 10, 2026

Once dismissed as speculative shortcuts, SPACs have evolved into a legitimate financing tool, especially for early-stage biotech. SL Bio’s $5.7B SPAC merger highlights why firms with long timelines and uncertain revenue may trade dilution and misaligned incentives for speed, certainty, and survival.

Racing the Mineral Bottleneck: EMAT’s Bet on Going Public Early
Author Image

Cayden Liu

Feb 4, 2026

The rush toward AI infrastructure and electrification has turned critical minerals into one of the most crowded trades of 2026. EMAT’s decision to enter public markets through a reverse merger offers speed and exposure, but little of the trust traditionally built through an IPO.

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto
Author Image

Yessica Jain

Feb 3, 2026

In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?
Author Image

Shaurya Vohra

Feb 2, 2026

Leveraged buyouts thrive on predictability. Video games do not. EA’s $55 billion take-private deal forces one of the most creatively volatile industries to operate under one of the most financially rigid ownership structures.

J&J’s Big Swing: The Single Pill Acquisition That Shook Biopharma
Author Image

Cayden Liu

Nov 19, 2025

Johnson & Johnson dropped $14.6 billion on a company whose value rests almost entirely on one psychiatric drug. Caplyta may be a blockbuster, or it may be the most expensive overreach in biotech since 2022. This is a high-risk, high-premium gamble at a moment when Big Pharma can’t afford missteps.

The $300 Billion Warning: Why Luxury's Summer Collapse Signals Crisis Ahead
Eliazar Marchenko's Profile Image

Eliazar Marchenko

Sep 21, 2025

LVMH’s sharpest sales drop since 2008 is more than a fashion story. Luxury’s downturn has historically foreshadowed recessions, and today it coincides with weakening confidence, asset stress, and slowing global demand.

The Congressman Betting Against America: What Tim Moore's TZA Trades Really Signal
Eliazar Marchenko's Profile Image

Eliazar Marchenko

Sep 10, 2025

As Vice Chairman of the Financial Services Committee, Tim Moore helps set the rules for America’s markets. He is also betting millions that those markets, and the small businesses they support, are about to fail.

Load More

Load More